BioNexus Gene Lab BGLC 深 沪
已收盘 10-09 16:00:00 美东时间
1.29
+0.041
+3.26%
华盛通- 最 高1.29
- 今 开1.2071
- 成交量 3875股
- 最 低 1.2071
- 昨 收 1.2493
- 总市值 378.41万
- 52周最高 5.8876
- 市盈率 静 --
- 换手率 0.13%
- 52周最低 1.07
- 委 比 99.68%
- 总股本 293.34万
- 历史最高 94.90
- 量 比 0.31
- 振 幅 6.64%
- 历史最低 1.07
- 每 手 1
- 风险率 1.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ruanyun Edai Technology Inks Agreement To Grant License To BioNexus Gene Lab For Its Cogni AI Document-Intelligence Platform For Healthcare In Malaysia
Ruanyun Edai Technology Inc. (NASDAQ: RYET) ("RYET" or the "Company") today announced that it has signed a definitive agreement under which, on closing, RYET would grant BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BGLC") an exclusive license of its Cogni AI document-intelligence platform for healthcare ...
10-05 21:02
RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
RYET has signed a definitive agreement with BGLC to grant an exclusive 20-year license for its Cogni AI platform in Malaysia's healthcare sector, receiving a 10% royalty on qualifying technology receipts and 560,000 BGLC shares. The partnership aligns with Malaysia's push to digitize its public healthcare system, with RYET's Formind Group strategy aiming to expand AI into new industries and markets. BGLC will lead local implementation, while RYET...
10-05 13:00
11 Industrials Stocks Moving In Wednesday's After-Market Session
Gainers Beam Glb (NASDAQ:BEEM) stock moved upwards by 22.7% to $1.49 during Wednesday's after-market session. The company's market cap stands at $25.5 million. As per the press release, Q2 earnings came out today. Polar Power (NASDAQ:POLA) stock increased by 20.75% to $1.92. The company's market cap...
08-20 05:05
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
Sam Tan, CEO of BioNexus Gene Lab Corp., spoke at the 2026 China-Malaysia Economic Cooperation Outlook Forum in Kuala Lumpur, discussing the potential for deepening biotechnology collaboration between China and Malaysia. He emphasized the need to move beyond traditional trade and into co-development, clinical validation, and regional healthcare access. Tan highlighted Malaysia's role as an ASEAN hub for clinical validation and commercialization, ...
05-29 13:00
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
BioNexus Gene Lab Corp. (BGLC) has appointed Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics, which focuses on advanced oncology testing and MRD liquid biopsy technologies. Fidelion commercializes the VitaGuard™ MRD technology globally, while BGLC has exclusive rights in Southeast Asia. Dr. Meyyappan, with over 15 years of experience in oncology diagnostics, will lead global commercial strategies. BGLC and Fidelion are adv...
03-11 12:45
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
BioNexus Gene Lab Corp. announced the restructuring of its subsidiary Chemrex Corporation Sdn. Bhd.'s board, streamlining it to two directors: Matthew L. Barsing as Chairman and Angeline Chong as Chief Financial Officer and Director. This restructuring aims to align Chemrex's governance with BioNexus's capital allocation and strategic evaluation frameworks. Chemrex remains a wholly owned subsidiary and continues to operate under BioNexus's oversi...
02-23 13:30
BioNexus Gene Lab Commences Its 2026 Deployment Phase For VitaGuard Minimal Residual Disease Platform
BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company"), a technology-driven precision diagnostics company, today announced the formal commencement of its 2026 Deployment Phase for the VitaGuard™
01-28 22:01
BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market
BioNexus Gene Lab Corp (BGLC) announced the commencement of its 2026 Deployment Phase for the VitaGuard™ Minimal Residual Disease (MRD) platform, aiming to make cancer monitoring more accessible and affordable across Southeast Asia. The platform is designed to disrupt high-cost legacy systems by targeting a cost profile below $3,000 per test. BGLC CEO Sam Tan emphasized the company's focus on regional strength and sustainable market capture, leve...
01-28 14:00
BioNexus Gene Lab Executes Intellectual Property License Agreement For Southeast Asia With Fidelion Diagnostics For VitaGuard Minimal Residual Disease Liquid Biopsy Platform
BioNexus Gene Lab Corp. ("BGLC") today announced that it has executed an Exclusive Intellectual Property License Agreement for Southeast Asia with Fidelion Diagnostics Pte. Ltd. ("Fidelion") for the VitaGuard™
2025-12-01 21:07
